© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
June 09, 2021
Patients with prostate cancer have to be approached differently depending on the state of their metastases.
June 06, 2021
If it were to be approved now, the drug would be used in patients with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor-directed therapy and 1 to 2 taxane-based chemotherapeutics.
The investigative therapy targets a specific molecule that is generally only expressed on the prostate cancer cell, according to a recent interview.
June 05, 2021
Medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.
Notably, the investigative treatment avoids many of the severe adverse effects common in traditional therapies.
June 04, 2021
The use of 177Lu-PSMA-617 resulted in a 60% reduction in radiographic progression or death among patients with advanced prostate cancer.
New research presented at the American Society of Clinical Oncology 2021 annual meeting has found encouraging results with the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.
Results from the phase 3 TITAN study shows a combination therapy that includes apalutamide may achieve survival benefit without significant burden of adverse effects.
June 02, 2021
Frequent prostate-specific antigen screenings may lower the risk of metastasis at the time of diagnosis and lower mortality risk from prostate cancer among younger African American men.
May 25, 2021
This discovery could enhance efforts to develop better treatments for breast, ovarian, and prostate cancer.